Pfizer Inc. has bought a new near-term commercial opportunity in a deal with Myovant Sciences Ltd. for the company's newly approved Orgovyx (relugolix), which was recently approved by the US Food and Drug Administration for prostate cancer and could also be approved for two women's health indications.
The two companies announced a development and commercialization agreement on 28 December, one week after Orgovyx was approved by the FDA for the treatment of advanced prostate cancer. (Also see "Keeping Track: Myovant, Almirall, MacroGenics Nab Novel Approvals; Novartis’ Inclisiran Delayed" - Pink Sheet, 22 December, 2020.) Pfizer agreed to pay $650m upfront in a deal valued at up to $4
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?